Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Leclerc

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 28, 1998
Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastomaK Kramer, N K Cheung, W L Gerald, et al.
Genes, Chromosomes & Cancer|August 10, 1999
Amplifications of DNA primase 1 (PRIM1) in human osteosarcomaW V Yotov, H Hamel, G E Rivard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
A population-based study of neuroblastoma incidence, survival, and mortality in North AmericaM L Bernstein, J M Leclerc, G Bunin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1990
Epstein-Barr virus polymorphic B-cell lymphoma associated with leukemia and with congenital immunodeficienciesJ H Joncas, P Russo, P Brochu, et al.
Cancer|December 1, 1995
Screening for neuroblastoma in North America. Preliminary results of a pathology review from the Quebec ProjectL A Takeuchi, Y Hachitanda, W G Woods, et al.
Journal of Pediatric Hematology/Oncology|August 13, 1999
Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapyM J Coppes, R Yanofsky, S Pritchard, et al.
Pediatric Blood & Cancer|January 16, 2018
Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: A prospective evaluationUma H Athale, T Mizrahi, C Laverdière, et al.
The American Journal of Pediatric Hematology/Oncology|November 1, 1992
Screening for neuroblastoma in North America. 2-year results from the Quebec ProjectW G Woods, M Tuchman, M L Bernstein, et al.
Progress in Clinical and Biological Research|January 1, 1994
Screening for neuroblastoma (NB) in North America: the Quebec ProjectW G Woods, B Lemieux, J M Leclerc, et al.
Medical and Pediatric Oncology|July 9, 1999
Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapyM J Coppes, R Lau, L C Ingram, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|March 28, 1998
Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastomaK Kramer, N K Cheung, W L Gerald, et al.
Genes, Chromosomes & Cancer|August 10, 1999
Amplifications of DNA primase 1 (PRIM1) in human osteosarcomaW V Yotov, H Hamel, G E Rivard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
A population-based study of neuroblastoma incidence, survival, and mortality in North AmericaM L Bernstein, J M Leclerc, G Bunin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1990
Epstein-Barr virus polymorphic B-cell lymphoma associated with leukemia and with congenital immunodeficienciesJ H Joncas, P Russo, P Brochu, et al.
Cancer|December 1, 1995
Screening for neuroblastoma in North America. Preliminary results of a pathology review from the Quebec ProjectL A Takeuchi, Y Hachitanda, W G Woods, et al.
Journal of Pediatric Hematology/Oncology|August 13, 1999
Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapyM J Coppes, R Yanofsky, S Pritchard, et al.
Pediatric Blood & Cancer|January 16, 2018
Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: A prospective evaluationUma H Athale, T Mizrahi, C Laverdière, et al.
The American Journal of Pediatric Hematology/Oncology|November 1, 1992
Screening for neuroblastoma in North America. 2-year results from the Quebec ProjectW G Woods, M Tuchman, M L Bernstein, et al.
Progress in Clinical and Biological Research|January 1, 1994
Screening for neuroblastoma (NB) in North America: the Quebec ProjectW G Woods, B Lemieux, J M Leclerc, et al.
Medical and Pediatric Oncology|July 9, 1999
Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapyM J Coppes, R Lau, L C Ingram, et al.
Pageof 5